TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33822898

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg at week 0, week 4, Q8W
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Guselkumab (both dosing regimens)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Guselkumab (resolved enthesitis at week 24)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Guselkumab (unresolved enthesitis at week 24)
Number of subjects: 1118
Study: 34049789

Group type: EXPERIMENTAL
Intervention: Risk prediction model incorporating institutional case volume
Number of subjects: 57804

Group type: EXPERIMENTAL
Intervention: Case volume classification (50 or less, 50-100, 100-200, or more than 200 average cardiac surgery cases per year)
Number of subjects: 57804
Study: 32555990

Group type: EXPERIMENTAL
Intervention: Intrathyroid injection of dexamethasone (IID)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 34664816

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg, twice a day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 41
Study: 32924685

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Number of subjects: 71
Study: 35240075

Group type: EXPERIMENTAL
Intervention: 12 cycles of venetoclax consolidation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimal residual disease-guided venetoclax consolidation
Number of subjects: 70
Study: 33860177

Group type: EXPERIMENTAL
Intervention: Psilocybin (20‐30 mg/70 kg) with overtone-based music
Number of subjects: 10

Group type: COMPARATOR
Intervention: Psilocybin (20‐30 mg/70 kg) with Western classical music
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Psilocybin (30 mg/70 kg) with chosen music (overtone-based or Western classical)
Number of subjects: 10
Study: 36352620

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32022647

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Psychodynamic Therapy (PDT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 47
Study: 33721839

Group type: EXPERIMENTAL
Intervention: Pleasant emotions
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Unpleasant emotions
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 466
Study: 33991112

Group type: EXPERIMENTAL
Intervention: 6 mm BOZD ortho-k lenses
Number of subjects: 70

Group type: COMPARATOR
Intervention: 5 mm BOZD ortho-k lenses
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 32680548

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (30 g/day) with hypocaloric diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (hypocaloric diet only)
Number of subjects: 60
Study: 34391275

Group type: EXPERIMENTAL
Intervention: Massage by a nurse
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Massage by patient's family
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 32379608

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 268
Study: 33395356

Group type: EXPERIMENTAL
Intervention: ORADUR-MPH
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35899977

Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (SL‐APO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg, positive control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32460773

Group type: EXPERIMENTAL
Intervention: Intensive upper limb rehabilitation added to botulinum toxin-A
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study: 35816069

Group type: EXPERIMENTAL
Intervention: Nutraceutical supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutraceutical supplement (after transitioning from placebo)
Number of subjects: 0
Study: 33067310

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 2 mg/kg (maximum 40 mg), once daily for 3 days
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 35300713

Group type: EXPERIMENTAL
Intervention: Ovarian endometriotic lesions
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Eutopic endometrium
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Stage IV ovarian endometriotic lesions
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Stage III ovarian endometriotic lesions
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of BDNF mRNA expression in eutopic endometrium
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of TrKB mRNA expression in eutopic endometrium
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of BDNF in eutopic and ectopic endometrium
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of TrKB in eutopic and ectopic endometrium
Number of subjects: 62
Study: 34622597

Group type: EXPERIMENTAL
Intervention: Low Dose - Deep Learning (LD-DL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal Dose - Iterative Reconstruction (ND-IR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low Dose - Filtered Back Projection (LD-FBP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low Dose - Iterative Reconstruction (LD-IR)
Number of subjects: 100
Study: 32919454

Group type: EXPERIMENTAL
Intervention: Cow's milk
Number of subjects: 96

Group type: COMPARATOR
Intervention: Soy milk substitute
Number of subjects: 96
Study: 36122260

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral retrolaminar block with 20 mL of 0.25% bupivacaine and 5 µg/mL adrenaline (1:200000)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ultrasound-guided thoracic epidural analgesia with 20 mL of 0.25% bupivacaine and 5 µg/mL adrenaline (1:200000)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral retrolaminar block
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ultrasound-guided thoracic epidural analgesia
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 52
Study: 32357109

Group type: EXPERIMENTAL
Intervention: Text Messaging
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Teenwork (TW)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: TW+Text
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 301
Study: 34614195

Group type: EXPERIMENTAL
Intervention: Daytime compression garment plus nighttime compression bandaging
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Daytime compression garment plus nighttime compression system garment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Daytime compression garment alone (standard care)
Number of subjects: 120
Study: 32285548

Group type: EXPERIMENTAL
Intervention: Colour vision testing using the Richmond Hardy-Rand-Rittler pseudoisochromatic test; diagnostic plates for determining CVD type and extent.
Number of subjects: 1626

Group type: COMPARATOR
Intervention: Traveller participants
Number of subjects: 1626

Group type: COMPARATOR
Intervention: Boys with CVD
Number of subjects: 1626
Study: 33382189

Group type: EXPERIMENTAL
Intervention: HBsAg-positive with high HBV DNA (≥2000 IU/ml)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Isolated anti-HBcAb-positive
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Resolved HBV infection (HBsAb-positive/HBcAb-positive)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: HBV non-immune/vaccinated (HBcAb-negative)
Number of subjects: 879
Study: 32710396

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (5 days at baseline, 3 days at 12 months)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 208
Study: 34773923

Group type: EXPERIMENTAL
Intervention: GSK3358699 (1-40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GSK3358699 (10 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GSK3358699 (20-40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GSK3358699 (40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GSK3358699
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 34986069

Group type: EXPERIMENTAL
Intervention: External Control Arm (ECA) created from patient-level data from previous clinical trials or real-world data.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control arm (not explicitly detailed in the abstract).
Number of subjects: 0
Study: 33752148

Group type: EXPERIMENTAL
Intervention: Single-dose carbohydrates (administered 2–3 h before surgery)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Double-dose carbohydrates (administered 10 h before surgery and 2–3 h before surgery)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Single-dose carbohydrates
Number of subjects: 139

Group type: COMPARATOR
Intervention: Double-dose carbohydrates
Number of subjects: 139
Study: 36453320

Group type: EXPERIMENTAL
Intervention: Short-term aerobic exercise (cycling at moderate intensity 20% Wmax for 10 minutes and high intensity 60% Wmax for 5 minutes)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Long-term aerobic exercise (regular jogging for 30 minutes, 20 times per month for 3 months)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (irregular exercise)
Number of subjects: 123
Study: 33970360

Group type: EXPERIMENTAL
Intervention: Polydisperse sample with avoided reconstruction mistakes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reconstruction mistakes in measuring propensity
Number of subjects: 0
Study: 32859978

Group type: EXPERIMENTAL
Intervention: S. epidermidis strains from endophthalmitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: S. epidermidis strains from healthy conjunctiva
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEGs associated with thioredoxin system and iron ion metabolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEGs associated with two-component system and pyruvate metabolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene SE1634
Number of subjects: 0
Study: 34355328

Group type: EXPERIMENTAL
Intervention: High pollution area (PM10: 121.44±43.49 μg/m3, PM2.5: 84.18±31.32 μg/m3)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Moderate pollution area (PM10: 89.7±37.34 μg/m3, PM2.5: 58±23.94 μg/m3)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Low pollution area (PM10: 59.14±25.24 μg/m3, PM2.5: 38.97±16.87 μg/m3)
Number of subjects: 369
Study: 34522871

Group type: EXPERIMENTAL
Intervention: L-arginine 1.66 g twice a day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 101
Study: 35606250

Group type: EXPERIMENTAL
Intervention: Nutraceutical preparation containing 3.75mg of monacolin K, 515mg of berberine and 50mg of coenzyme Q10 per tablet (Lipok®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32537828

Group type: EXPERIMENTAL
Intervention: Single Simple Question (SSQ)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: MG impairment index
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic (ROC) curve for PASS and SSQ
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: SSQ score threshold
Number of subjects: 157
Study: 36493607

Group type: EXPERIMENTAL
Intervention: Culprit artery percutaneous coronary intervention during the index procedure
Number of subjects: 7473

Group type: EXPERIMENTAL
Intervention: OCA group
Number of subjects: 7473
Study: 33765860

Group type: EXPERIMENTAL
Intervention: PCCP training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Service planning as usual (Control)
Number of subjects: 60
Study: 33177727

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 300

Group type: COMPARATOR
Intervention: Natural delivery without analgesic measures
Number of subjects: 300
Study: 34843987

Group type: EXPERIMENTAL
Intervention: Achieved primary end point of sustained corticosteroid-free clinical remission with no ulcers on ileocolonoscopy at week 54
Number of subjects: 95

Group type: COMPARATOR
Intervention: Did not achieve primary end point of sustained corticosteroid-free clinical remission
Number of subjects: 95
Study: 33647599

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 0
Study: 32713693

Group type: COMPARATOR
Intervention: Pelleted starter conditioned for 0 min (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pelleted starter conditioned for 2 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pelleted starter conditioned for 4 min
Number of subjects: 30
Study: 35140156

Group type: EXPERIMENTAL
Intervention: Web-based education intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard education (Control)
Number of subjects: 85
Study: 33858214

Group type: EXPERIMENTAL
Intervention: Concussion Cohort (24 to 48 hours post-injury)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Subconcussion Cohort (non-concussed participants with moderate or high cumulative subconcussive impact exposure)
Number of subjects: 167
Study: 36095045

Group type: EXPERIMENTAL
Intervention: Pain Science Education (PSE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pathoanatomical Education (PAE)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (PSE and PAE)
Number of subjects: 66
Study: 33492514

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (APT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no APT)
Number of subjects: 160
Study: 34850238

Group type: EXPERIMENTAL
Intervention: digital cognitive behavior therapy for insomnia (dCBT‐I)
Number of subjects: 208

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 208
Study: 32550713

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 35857186

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32605552

Group type: EXPERIMENTAL
Intervention: Community-based cooking program
Number of subjects: 0
Study: 32852366

Group type: EXPERIMENTAL
Intervention: rhBMP‐2 (INFUSE bone graft) added to standard surgical procedure
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard surgical procedure without rhBMP‐2
Number of subjects: 5
Study: 32086189

Group type: EXPERIMENTAL
Intervention: SoMe social media literacy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health lessons as usual (control)
Number of subjects: 0
Study: 36495861

Group type: EXPERIMENTAL
Intervention: Genomics-guided therapies, standardized system for determining actionability of genomic alterations
Number of subjects: 0
Study: 34814896

Group type: EXPERIMENTAL
Intervention: High Tone Power Therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (without High Tone Power Therapy)
Number of subjects: 35
Study: 32696704

Group type: COMPARATOR
Intervention: Sugar-Sweetened Beverages (SSBs)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Artificially Sweetened Beverages (ASBs)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Unsweetened Beverages (USBs)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Comparison between ASB and USB groups
Number of subjects: 203
Study: 34575662

Group type: EXPERIMENTAL
Intervention: DRSS-guided management
Number of subjects: 40

Group type: COMPARATOR
Intervention: PLI-guided management
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 40
Study: 35608001

Group type: EXPERIMENTAL
Intervention: Global budget intervention for county hospitals
Number of subjects: 22000000
Study: 33766829

Group type: EXPERIMENTAL
Intervention: Novel MR imaging scoring system for hypoxic-ischemic brain injury
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Adjusted scoring system
Number of subjects: 252
Study: 36335376

Group type: EXPERIMENTAL
Intervention: Proactive Outreach with Medication Opt‐out for Tobacco Treatment Engagement (PrOMOTE)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 230
Study: 33783518

Group type: EXPERIMENTAL
Intervention: Emotionally resilient phenotype (419 individuals, 23.8%)
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Cognitively impaired phenotype (368 individuals, 20.9%)
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Cognitively resilient phenotype (620 individuals, 35.3%)
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Neuropsychiatrically distressed phenotype (350 individuals, 19.9%)
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Latent profile (LP) analysis
Number of subjects: 1757
Study: 35802618

Group type: EXPERIMENTAL
Intervention: Pre-operative hypnosis session and post-operative web-based Acceptance and Commitment Therapy (ACT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pre-operative one-session mindfulness through an audio file and post-operative treatment as usual (TAU)
Number of subjects: 200
Study: 36355373

Group type: EXPERIMENTAL
Intervention: LINKAGE intervention (6 group-based sessions emphasizing patient agency, skill, and motivation; facilitated connection with primary care practitioner)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: LINKAGE intervention
Number of subjects: 503

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 503
Study: 33357793

Group type: EXPERIMENTAL
Intervention: Comic-based learning tool for blood transfusion training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional standard operational procedure
Number of subjects: 0
Study: 35358441

Group type: EXPERIMENTAL
Intervention: Standard of care plus rituximab (375 mg/m2 on days 3, 10, 17, and 24)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Standard of care plus rituximab
Number of subjects: 586
Study: 34824985

Group type: EXPERIMENTAL
Intervention: Online personalized feedback intervention
Number of subjects: 744

Group type: COMPARATOR
Intervention: Educational materials only (Control)
Number of subjects: 744
Study: 36115523

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg daily
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Apremilast 30 mg twice a day
Number of subjects: 1020
Study: 32914482

Group type: EXPERIMENTAL
Intervention: Eating disorders (EDs)
Number of subjects: 1657

Group type: COMPARATOR
Intervention: Non-eating disorder controls
Number of subjects: 1657
Study: 34699857

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Combination of bright light therapy and fluoxetine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo-sham control
Number of subjects: 122
Study: 33907251

Group type: EXPERIMENTAL
Intervention: Chloroquine 450 mg BID on day 1 and 450 mg once daily from days 2 to 5 or Hydroxychloroquine 400 mg BID on day 1 and 400 mg once daily from days 2 to 5 (combined with standard care)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chloroquine/hydroxychloroquine (combined with standard care)
Number of subjects: 105
Study: 36421046

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 33743063

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of 20-mg dexamethasone (Group B)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Two perioperative doses of 10-mg dexamethasone (Group C)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No dexamethasone (Group A)
Number of subjects: 3
Study: 33256688

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) intervention for reduction of blood pressure
Number of subjects: 0
Study: 35621327

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention (16 sessions of cognitive tasks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no cognitive stimulation)
Number of subjects: 59
Study: 33610726

Group type: EXPERIMENTAL
Intervention: French maritime pine bark extract (PBE) supplementation (50mg, two capsules/day for eight weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 32511669

Group type: EXPERIMENTAL
Intervention: Raising Healthy Children intervention (full intervention)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 182
Study: 36244383

Group type: EXPERIMENTAL
Intervention: Dedicated care
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Designated care
Number of subjects: 1340

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1340
Study: 33010148

Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 486

Group type: COMPARATOR
Intervention: No dapagliflozin treatment (Control)
Number of subjects: 486
Study: 35819522

Group type: EXPERIMENTAL
Intervention: 30‐s sit‐to‐stand (30STS) test
Number of subjects: 120
Study: 34620093

Group type: EXPERIMENTAL
Intervention: Desflurane at concentrations of 0.3, 0.6, and 0.9 MAC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane at concentrations of 0.3, 0.6, and 0.9 MAC
Number of subjects: 40